SUMMIT THERAPEUTICS PLC

NASDAQ: SMMT (Summit Therapeutics Inc.)

Last update: 14 hours ago

16.19

-0.26 (-1.58%)

  • 1D -1.58%
  • 5D -10.21%
  • 1M -13.65%
  • 6M -37.37%
  • YTD -11.77%
  • 1Y -15.63%
  • 5Y 267.95%
Previous Close 16.45
Open 16.42
Volume 2,763,841
Avg. Volume (3M) 3,995,204
Market Cap 12,052,525,056
Price / Book 62.69
52 Weeks Range
15.55 (-3%) — 36.91 (127%)
Earnings Date 20 Oct 2025
Diluted EPS (TTM) -0.340
Total Debt/Equity (MRQ) 1.87%
Current Ratio (MRQ) 10.63
Operating Cash Flow (TTM) -173.14 M
Levered Free Cash Flow (TTM) -104.80 M
Return on Assets (TTM) -52.50%
Return on Equity (TTM) -123.93%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Summit Therapeutics Inc. Bullish Bullish

AIStockmoo Score

0.8
Analyst Consensus 3.5
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages -2.5
Technical Oscillators -2.5
Average 0.75

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SMMT 12 B - - 62.69
ROIV 14 B - - 3.27
BMRN 11 B - 20.33 1.74
CRSP 5 B - - 2.52
REGN 80 B 0.35% 18.11 2.50
HALO 8 B - 14.84 16.35

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Sector Healthcare
Industry Biotechnology
Investment Style Mid Core
% Held by Insiders 84.32%
% Held by Institutions 13.52%

Ownership

Name Date Shares Held
Pictet Asset Management Holding Sa 30 Sep 2025 1,604,163
Apeiron Capital Ltd 30 Sep 2025 1,310,941
Nomura Holdings Inc 30 Sep 2025 1,048,927
52 Weeks Range
15.55 (-3%) — 36.91 (127%)
Price Target Range
16.00 (-1%) — 40.00 (147%)
High 40.00 (HC Wainwright & Co., 147.07%) Buy
40.00 (Guggenheim, 147.07%) Buy
40.00 (JMP Securities, 147.07%) Buy
40.00 (Citigroup, 147.07%) Buy
Median 40.00 (147.07%)
Low 16.00 (Barclays, -1.17%) Sell
Average 35.20 (117.42%)
Total 4 Buy, 1 Sell
Avg. Price @ Call 19.34
Firm Date Target Price Call Price @ Call
Guggenheim 22 Oct 2025 40.00 (147.07%) Buy 19.16
04 Sep 2025 40.00 (147.07%) Buy 23.80
Barclays 21 Oct 2025 16.00 (-1.17%) Sell 18.74
17 Sep 2025 13.00 (-19.70%) Sell 18.09
HC Wainwright & Co. 21 Oct 2025 40.00 (147.07%) Buy 18.74
16 Sep 2025 50.00 (208.83%) Buy 18.12
Citigroup 20 Oct 2025 40.00 (147.07%) Buy 20.04
JMP Securities 20 Oct 2025 40.00 (147.07%) Buy 20.04
03 Sep 2025 40.00 (147.07%) Buy 23.52

No data within this time range.

  • 3M
Date Type Details
07 Nov 2025 Announcement Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
04 Nov 2025 Announcement Summit Therapeutics to Present at Upcoming Investor Conferences
31 Oct 2025 Announcement Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
22 Oct 2025 Announcement Summit Therapeutics Raises $500 Million in Private Placement
20 Oct 2025 Announcement Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
19 Oct 2025 Announcement Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
17 Oct 2025 Announcement Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
15 Oct 2025 Announcement Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
24 Sep 2025 Announcement HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
24 Sep 2025 Announcement Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Sep 2025 Announcement Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
07 Sep 2025 Announcement Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
03 Sep 2025 Announcement Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria